ASTEC718.10

Astec LifeSciences Limited

· Chemicals
₹ CrorePeersPUNJABCHEMMOLIPLINSECTICIDDHARMAJBHARATRASADVANCEHERANBAMcap ₹1,600 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity-12.70-57.34-20.70-20.70
Return on Assets-4.81-15.28-8.59-8.59
Return on Capital Employed-7.30-21.31-11.18-11.18
Return on Invested Capital-3.71-13.31-5.95-4.65
Margins
EBITDA Margin-1.29-17.36-1.011.31
Operating Margin-9.20-28.83-11.03-11.03
Incremental Operating Margin88.1390.47
Pretax Margin-13.48-36.98-18.07-15.14
Net Income Margin-10.23-35.33-18.05-15.10
Net Income to Common Margin-10.24-35.34-18.06-15.11
FCF Margin-27.34-7.93-19.24-19.24
Additional
Effective Tax Rate24.064.450.150.25
Dvd Payout Ratio-6.27-0.00-0.00
Sustainable Growth Rate-13.50-57.34-20.70-20.70
Incremental Operating Margin %88.1390.47-142.95
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.